Cannabidiol reduced the frequency of convulsive seizures compared with placebo in Dravet syndrome, a childhood epilepsy disorder with a high mortality rate and no approved treatment in the United States, reported a clinical trial in the New England Journal of Medicine.
The study randomly assigned 120 children and young adults with the syndrome and drug-resistant seizures to receive either cannabidiol (20 mg/kg of body weight per day) or placebo, in addition to standard antiepileptic treatment.
Slomski A. Fewer Seizures With Cannabidiol in Catastrophic Epilepsy. JAMA. 2017;318(4):323. doi:10.1001/jama.2017.8846
Customize your JAMA Network experience by selecting one or more topics from the list below.